Coronavirus updates: Trump says 'not much' he'd change about COVID response
Thirty-one states are considered in the red zone for new cases in the last week.
A pandemic of the novel coronavirus has now killed more than 1.1 million people worldwide.
Over 40.7 million people across the globe have been diagnosed with COVID-19, the disease caused by the new respiratory virus, according to data compiled by the Center for Systems Science and Engineering at Johns Hopkins University. The criteria for diagnosis -- through clinical means or a lab test -- has varied from country to country. Still, the actual numbers are believed to be much higher due to testing shortages, many unreported cases and suspicions that some national governments are hiding or downplaying the scope of their outbreaks.
Since the first cases were detected in China in December, the virus has rapidly spread to every continent except Antarctica.
The United States is the worst-affected country, with more than 8.2 million diagnosed cases and at least 220,955 deaths.
California has the most cases of any U.S. state, with more than 883,000 people diagnosed, according to Johns Hopkins data. California is followed by Texas and Florida, with over 862,000 cases and over 760,000 cases, respectively.
More than 190 vaccine candidates for COVID-19 are being tracked by the World Health Organization, at least 10 of which are in crucial phase three studies. Of those 10 potential vaccines in late-stage trials, there are currently five that will be available in the United States if approved.
Latest headlines:
- Trump says there's 'not much' he'd do differently with COVID response
- COVID-19 patients in hospitals 5 times more likely to die than those hospitalized with flu, CDC says
- Cuomo discourages New Yorkers from unnecessary travel to NJ, PA, CT
- More states in 'red zone,' per White House task force
- Analysis shows rise in COVID-19 hospitalizations in 41 US states
US reports more than 58,000 new cases as death toll tops 220,000
There were 58,387 new cases of COVID-19 identified in the United States on Monday, according to a real-time count kept by Johns Hopkins University.
The latest daily tally is up by more than 10,000 from the previous day but remains under the country’s record set on July 16, when there were 77,255 new cases in a 24-hour-reporting period.
An additional 445 coronavirus-related fatalities were also recorded Monday, up by 56 from the previous day's death toll and down from a peak of 2,666 new fatalities reported on April 17.
A total of 8,214,754 people in the United States have been diagnosed with COVID-19 since the pandemic began, and at least 220,133 of them have died, according to Johns Hopkins. The cases include people from all 50 U.S. states, Washington, D.C. and other U.S. territories as well as repatriated citizens.
By May 20, all U.S. states had begun lifting stay-at-home orders and other restrictions put in place to curb the spread of the novel coronavirus. The day-to-day increase in the country's cases then hovered around 20,000 for a couple of weeks before shooting back up and crossing 70,000 for the first time in mid-July. The daily tally of new cases has gradually come down since then but has started to climb again in recent weeks.
The number of new COVID-19 cases recorded in the United States continued to increase by double digits in week-over-week comparisons, while the number of new deaths from the disease also ticked upward, according to an internal memo from the U.S. Department of Health and Human Services that was obtained by ABC News on Monday night.
UK to launch controversial vaccine trials where volunteers will be infected
In a bid to speed up the race to find a vaccine for the novel coronavirus, the U.K. government announced Tuesday morning that it will be launching some controversial vaccine studies known as challenge trials.
In a world first for COVID-19, young healthy volunteers will be vaccinated, then intentionally exposed to the potentially deadly virus in order to test vaccines in a controlled environment. Although some medical experts view them as ethically questionable, the benefit of challenge trials is that they can be completed in a much shorter timeframe than typical late-stage studies.
The experiment will take place in a quarantine ward of a hospital in north London. After inhaling a diluted dose of the virus, the trial participants will be closely monitored, thus enabling scientists and doctors to better understand the disease and how a vaccine can fight it.
"Human challenge studies can increase our understanding of COVID-19 in unique ways and accelerate development of the many potential new COVID-19 treatments and vaccines," said Dr. Chris Chiu of Imperial College London's Department of Infectious Disease, a lead researcher on the human challenge study.
ABC News' Zoe Magee contributed to this report.